

Title (en)

COMPOSITION OF MESALAZINE ENTERIC TABLET FORMULATION

Title (de)

ZUSAMMENSETZUNG EINER MESALAZIN-ENTERUSTABLETTENFORMULIERUNG

Title (fr)

COMPOSITION DE FORMULATION DE COMPRIMÉ ENTÉRIQUE À BASE DE MÉSALAZINE

Publication

EP 4340847 A4 20240717 (EN)

Application

EP 21940969 A 20210521

Priority

TR 2021050472 W 20210521

Abstract (en)

[origin: WO2022245307A1] A formulation of a pharmaceutical enteric tablet composition comprising mesalazine, a process for the production of said formulation with a multilayer enteric coating that provides required in-vitro dissolution profiles showing the specific delivery of the active substance contained in the dosage form to the colon initially and during storage under stability conditions.

IPC 8 full level

A61K 31/606 (2006.01); **A61J 3/00** (2006.01); **A61K 9/16** (2006.01); **A61K 9/28** (2006.01); **A61P 1/04** (2006.01)

CPC (source: EP)

A61J 3/005 (2013.01); **A61K 9/1652** (2013.01); **A61K 9/2846** (2013.01); **A61K 9/2886** (2013.01); **A61K 31/606** (2013.01); **A61P 1/04** (2018.01)

Citation (search report)

- [YD] US 2012282333 A1 20121108 - KAKUMANU VASU KUMAR [IN], et al
- [Y] CA 2187741 A1 19951102 - YAMANOUCHI PHARMA CO LTD [JP]
- [Y] ANONYMOUS: "Summary of Product Characteristics (SmPC) for Salofalk 500 mg gastro-resistant tablets", MEDICINES.ORG, 1 January 2018 (2018-01-01), pages 1 - 5, XP055534701, Retrieved from the Internet <URL:https://www.medicines.org.uk/emc/product/5785/smpc/print> [retrieved on 20181214]
- See also references of WO 2022245307A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022245307 A1 20221124; EP 4340847 A1 20240327; EP 4340847 A4 20240717

DOCDB simple family (application)

TR 2021050472 W 20210521; EP 21940969 A 20210521